Evaluation of the dynamics of the glomerular filtration rate in patients with chronic kidney disease according to the data of the regional register


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Chronic kidney disease (CKD) is a global public health problem worldwide, associated with an increased risk of cardiovascular and all-cause mortality. objective. identification of the regional features of the causes and rate of progression of ckd in the northern territory. material and methods. the data of the registry of 484 patients of the nephrology department of the Komi republican clinical hospital for 2015-2018 were used; there were 231 (47.7%) men and 253 (52.3%) women. The mean age was 58.8±15.8 years. results. the number of patients with 1 visit - 314, with 2 or more visits - 170 patients. the mean glomerular filtration rate (GFR) was 30.1±19.3 ml/min/1.73 m2. distribution by ckd stages: stage 1 ckd - 1.2%, 2 - 5.6%, 3a - 13.6%, 3b - 12.4%, 4 - 26.4% , 5 - 26.6%. the main causes of ckd: tubulointerstitial nephritis (21.5%), diabetic nephropathy (16.7%), chronic glomerulonephritis (15.7%), hypertensive nephropathy (12.0%), the diagnosis is not defined (12.8%). the average decrease in gfr was 3.99±2.7 ml/min/1.73 m2 during the year of follow-up. in patients with stage 2 ckd, gfr increased by 8.4 ml/ min/1.73 m2 per year, with stage 3 ckd - a decrease by 0.13 ml/min/1.73 m2 per year, with stage 4 - decrease by 5.17, with stage 5 - decrease by 6.8 ml/min/1.73 m2 per year (p=0.034). a direct association of the rate of impairment of renal function with the level phosphate, urea, potassium, proteinuria, esr levels, and an inverse association with the o hemoglobin, gfr levels was revealed. the most frequently prescribed drugs for the treatment of patients were angiotensin-converting enzyme inhibitors (32.4%), calcium channel blockers (47.5%), statins (36.4%), ß-BLOCKERS (35.1%), diuretics (24, 6%), antiplatelet agents (39.9%). Conclusion. Maintenance of a ckd registry allows to identify regional features of ckd and assess the rate of progression of ckd.

Full Text

Restricted Access

About the authors

Olga N. Kurochkina

Pitirim Sorokin Syktyvkar State University

Email: olga_kgma@mail.ru
Professor at the Department of Therapy, Medical Institute Republic of Komi, Syktyvkar, Russia

Sevil N. Kerimova

Komi Republican Oncological Dispensary

Oncologist of the Department of Antitumor Drug Therapy Republic of Komi, Syktyvkar, Russia

Zaur B. Ismailov

Pitirim Sorokin Syktyvkar State University

Email: tomclancy20000@gmail.com
Senior Laboratory Assistant at the Institute of Biology Republic of Komi, Syktyvkar, Russia

Tatyana A. Yagupova

Komi Republican Clinical Hospital

Email: yagupovata@mail.ru
Head of the Nephrology Department, Chief Freelance Expert in Nephrology of the Ministry of Health of the Komi Republic Republic of Komi, Syktyvkar, Russia

References

  1. Crews D.C., Bello A.K., Saadi G. 2019 World Kidney Day Editorial - burden, access, and disparities in kidney disease. J. Bras. Nefrol. 2019;41(1):1-9. doi: 10.1590/2175-8239-JBN-2018-0224. [Epub 2019 Feb 28. Article in English, Portuguese].
  2. National Kidney Foundation K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am. J. Kidney Dis 2002;39(Suppl. 1):S1-266. Doi: CliCa0405689692.
  3. KDIGO 2012 Clinical Practice Guidelines for the Evaluation and Management of Chronic Kidney Disease. http://www.kdigo.org/clinical_practice_guidelines/pdf/CKD/KDIGO_2012_CKD_GL.pdf. doi: 10.1007/s11255-014-0761-7.
  4. Смирнов А.В., Шилов Е.М., Добронравов В.А. и др. Национальные рекомендации. Хроническая болезнь почек: основные принципы скрининга, диагностики, профилактики и подходы к лечению. Нефрология 2012;16(1):89-115.
  5. Моисеев В.С., Мухин Н.А., Смирнов А.В. и др. Национальные рекомендации: Сердечно-сосудистый риск и хроническая болезнь почек: стратегии кардионефропротекции. Рос. кардиол. журн. 2014;8(112):7-37. doi: 10.15829/1560-4071-2014-8-7-37.
  6. United States Renal Data System. 2018 USRDS annual data report: Epidemiology of kidney disease in the United States. National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, MD, 2018.
  7. Bello A.K., Ronksley P.E., Tangri N., et al. Prevalence and Demographics of CKD in Canadian Primary Care Practices: A Cross-sectional Study. Kidney Int. Rep. 2019;4(4):561- 70. doi: 10.1016/j.ekir.2019.01.005. eCollection 2019 Apr.
  8. Hasan M., Sutradhar I., Gupta R.D., Sarker M. Prevalence of chronic kidney disease in South Asia: a systematic review. BMC. Nephrol. 2018;19(1):291. doi: 10.1186/s12882-018-1072-5.
  9. Brück K., Stel V.S., Gambaro G., et al. European CKD Burden Consortium (2015). CKD Prevalence Varies across the European General Population. J. Am. Soc. Nephrol. 2016;27(7):2135-47. doi: 10.1681/ASN.2015050542.
  10. Hill N.R., Fatoba S.T., Oke J.L., et al. (2016) Global Prevalence of Chronic Kidney Disease - A Systematic Review and Meta-Analysis. PLoS. ONE. 2016;11(7):e0158765. doi: 10.1371/journal.pone.0158765.
  11. Coresh J. Update on the Burden of CKD. J. Am. Soc. Nephrol. 2017;28. doi: 10.1681/ASN.2016121374.
  12. Шамхалова М.Ш., Викулова О.К., Железнякова А.В. и др. Эпидемиология хронической болезни почек в Российской Федерации по данным федерального регистра взрослых пациентов с сахарным диабетом (2013-2016 гг.). Сахарный диабет. 2018;21(3):160-69. doi: 10.14341/DM9392.
  13. Lee C., Yun H.R., Joo Y.S., et al. Framingham risk score and risk of incident chronic kidney disease: A community-based prospective cohort study.Kidney Res. Clin. Pract. 2019;38(1):49-59. doi: 10.23876/f.krcp.18.0118.
  14. Курочкина О.Н., Нужный В.П. Сосудистый континуум у больных с терминальной почечной недостаточностью в условиях Севера. Известия Коми Научного Центра. 2012;4(12):49-53.
  15. Курочкина О.Н., Богомолов А.Н., Кузнецов А.В. Значение определения функции почек при построении прогностической модели неблагоприятных исходов у больных инфарктом миокарда с подъемом сегмента ST. Клин. нефрология. 2013;3:24-9.
  16. Курочкина О.Н., Хохлов А.Л., Кузнецов А.В. Клиническое течение и исходы инфаркта миокарда у женщин. Кардиология. 2013;53(8):54-9.
  17. Matsushita K., van der Velde M., Astor B.C., et al. Chronic Kidney Disease Prognosis Consortium. Association of estimated glomerular filtration rate and albuminuria with allcause and cardiovascular mortality in general population cohorts: a collaborative metaanalysis. Lancet. 2010;375(9731):2073-81. doi: 10.1016/S0140-6736(10)60674-5.
  18. Ejerblad E.C., Fored M., Lindblad P., et al. Association between smoking and chronic renal failure in a nationwide populationbasedcasecontrol study. JASN 2004;15(8).
  19. Schwarzinger M., Thiebaut S.P., Baillot S., et al. Alcohol use disorders and associated chronic disease - a national retrospective cohort study from France. BMC Public Health. 2017;18(1):43. [Epub 2017/07/25. PMID: 28732487].
  20. Shankar A., Klein R., Klein B.E. The association among smoking, heavy drinking, and chronic kidney disease. American J. Epidemiol. 2006;164(3):263-71. [Epub 2006/06/16. PMID: 16775042].
  21. Biesenbach G., Janko O., Zazgornik J. Similar rate of progression in the predialysis phase in type I and type II diabetes mellitus. Nephrol. Dial. Transplant 1994;9:1097.
  22. Ejerblad E., Fored M.C., Lindblad P., et al. Obesity and the risk of chronic renal failure. J. Am. Soc. Nephrol. 2006;17:1695-702.
  23. Yamakawa T., Tanaka S., Kamei J., et al. Phosphatidylinositol-3-kinase in angiotensin-II-induced hypertrophy of vascular smooth muscle cells. Eur. J. Pharmacol. 2003;478:39-46.
  24. https://ria.ru/20190911/1558534727.html дата обращения 08.04.2020.
  25. О состоянии санитарно-эпидемиологического благополучия населения в Российской Федерации в 2018 г.: Государственный доклад. М.: Федеральная служба по надзору в сфере защиты прав потребителей и благополучия человека, 2019. 254 с.
  26. https://www.bnkomi.ru/data/news/93018. Дата обращения 08.04.2020.
  27. https://iz.ru/859881/2019-03-23/rosstat-izuchil-rossiiskikh-kurilshchikov Дата обращения 08.04.2020.
  28. Муромцева Г.А., Концевая А.В., Константинов В.В. и др. Распространенность факторов риска неинфекционных заболеваний в российской популяции в 2012-2013 гг. Результаты исследования ЭССЕ-РФ. Кардиоваскулярнаятерапия и профилактика.2014;13(6):4-11.https://doi.org/10.15829/1728-8800-2014-6-4-11
  29. Kumela G.K., Desalegn W.A., Kerga D.F., et al. Patient Awareness, Prevalence, and Risk Factors of Chronic Kidney Disease among Diabetes Mellitus and Hypertensive Patients at Jimma University Medical Center, Ethiopia. Biomed. Res.Int. 2019;2019:2383508. doi: 10.1155/2019/2383508.eCollection 2019.
  30. Razavian M., Heeley E.L., Perkovic V., et al. Cardiovascular risk management in chronic kidney disease in general practice (the AusHEART study). Nephrol. Dial. Transplant. 2012;27(4):1396-402.
  31. Андрусев А.М., Перегудова Н.Г., Шинкарев М.Б., Томилина Н.А. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации 2014-2018 гг. Краткий отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества. ОООН «Российское Диализное Общество». 2019.
  32. Robinson B.M, Zhang J., Morgenstern H., et al. Worldwide, mortality risk is high soon after initiation of hemodialysis. Kidney Int. 2014;85(1):158-65.
  33. Foley R.N., Chen S-C., Solid C.A., et al. Early mortality in patients starting dialysis appears to go unregistered. Kidney Int. 2014; 86(2):392-98.
  34. Шутов А.М. Хроническая болезнь почек - глобальная проблема XXIвека. Клин. медицина. 2014;92(5):5-10.
  35. Курочкина О.Н., Ерушева Е.В., Курочкина Н.А., Вундервальд Д.С. Динамика функции почек и реальная клиническая практика лечения больных постифарктным кардиосклерозом. Клин. нефрология. 2012;5-6:38-40.
  36. Курочкина О.Н. Оценка функции почек с использованием показателя скорости клубочковой фильтрации в амбулаторно-поликлинической практике. Клин. нефрология. 2012;4:35-8.
  37. Томилина Н.А., Андрусев А.М., Перегудова Н.Г. и др. Заместительная терапия терминальной хронической почечной недостаточности в Российской Федерации в 2010-2015 гг. Отчет по данным Общероссийского Регистра заместительной почечной терапии Российского диализного общества. Нефрология и диализ. Приложение. 2017;19(4). doi: 10.28996/1680-4422-2017-4Suppl-1-95.
  38. Земченков А.Ю. Конакова И.Н. Темпы прогрессирования хронической болезни почек по данным Санкт-Петербургского городского регистра ХБП. Нефрология и диализ. 2015;17(1):34-51.
  39. Ягупова Т.А., Керимова С.Н., Исмаилов З.Б., Курочкина О.Н. Регистр хронической болезни почек в Республике Коми за 2015-2016 гг. Здоровье человека на Севере. 2018;1:18-21.
  40. Aiumtrakul N., Euswas K., Phichedwanichskul K., et al. Cardiovascular and Renal Outcomes in an Excellent Chronic Kidney Disease Clinic Compared with an Outpatient Clinic in a Primary Care Setting: A Retrospective Cohort Study. Kidney Dis. (Basel). 2019;5(3):144-52. doi: 10.1159/000495464. [Epub 2019 Jan 3].
  41. Marie Patrice H., Joiven N., Hermine F., et al. Factors associated with late presentation of patients with chronic kidney disease in nephrology consultation in Cameroon-a descriptive cross-sectional study. Ren. Fail. 2019;41(1):384-92. doi: 10.1080/0886022X.2019.1595644.
  42. Kumela Goro K., Desalegn Wolide A., Kerga Dibaba F., et al. Patient Awareness, Prevalence, and Risk Factors of Chronic Kidney Disease among Diabetes Mellitus and Hypertensive Patients at Jimma University Medical Center, Ethiopia. Biomed. Res.Int. 2019;2019:2383508. doi: 10.1155/2019/2383508.eCollection 2019.
  43. ERA-EDTA Registry: ERA-EDTA Registry Annual Report 2017. https://era-edta-reg.org/files/annualreports/pdf/AnnRep2017.pdf (date of the application November 20, 2019).
  44. Perazella M.A., Izzedine H. New drug toxicities in the onco-nephrology world. Kidney Int. 2015;87:909-17.
  45. Goldstein S.L., Kirkendall E., Nguyen H. Electronic health record identification of nephrotoxin exposure and associated acute kidney injury. Pediatr. 2013;132:e756-67.
  46. Harris P.S., Roy S.R., Coughlan C., et al. Chronic ethanol consumption induces mitochondrial protein acetylation and oxidative stress in the kidney. Redox Biol. 2015;6:33-40. doi: 10.1016/j.redox.2015.06.021. [Epub 2015 Jul 6].
  47. Varga Z., Matyas C., Paloczi J., Pacher P. Alcohol Misuse, and Kidney Injury: Epidemiological Evidence and Potential Mechanisms. Alcohol Res. Curr. Rev. 2017;38:283-88.
  48. Pan C.S., Ju T.R., Lee C.C., et al. Alcohol use disorder tied to development of chronic kidney disease: A nationwide database analysis. High connection between AUD и CKD. PLoS One. 2018;13(9):e0203410. doi: 10.1371/journal.pone.0203410. eCollection 2018.
  49. Orth S.R. Effects of smoking on systemic and intrarenal hemodynamics: influence on renal function. J. Am. Soc. Nephrol. 2004;15(Suppl. 1):S5863.
  50. Pabon M.A., Patino E., Bhatia D., at al. Beclin-1 regulates kidney damage caused by cigarette smoke in a mouse model of chronic obstructive pulmonary disease. JCI Insight. 2018;3(18). pii: 99592. doi: 10.1172/jci.insight.99592.
  51. Sandhu J.S. Smoking - a renal riskfactor. J. Assoc. Phys. India. 2003;51:9002. Review.
  52. Briganti E.M., Branley P., Chadban S.J., at al. Smoking is associated with renal impairment and proteinuria in the normal population: the Aus Diab. Kidney Study. Australian Diabetes, Obesity and Lifestyle Study. Am. J. Kidney Dis. 2002;40(4):70412.
  53. Keyzer C.A., van Breda G.F., Vervloet M.G. Effects of vitamin D receptor activation and dietary sodium restriction on residual albuminuria in CKD: theViRTUE-CKD trial. J. Am. Soc. Nephrol. 2017;28:1296-305.
  54. Соколова А.В., Драгунов Д.О., Арутюнов Г.П. и др. Влияние избыточного потребления соли на изменение тубулоинтерстициальной ткани почек пациентов с гипертонической болезнью. Морфологическое исследование. Клин. нефрология. 2017;4:42-50.
  55. Porter L.E., Hollenberg N.K. Obesity, salt intake and renal perfusion in healthy people. Hypertens. 1998;32:144-48.
  56. Jindal A., Brietzke S., Sowers J.R. Obesity and cardiorenal metabolic syndrome: treatment methods and their effectiveness in improving cardiovascular and renal risk factors. Cardiorenal. Honey. 2012;2:314-17.
  57. Susic D., Frohlich E.D. Hyperuricemia: a biomarker of renal hemodynamics. Cardiorenal. Honey. 2015;5:175-82.
  58. Hsu C.Y., McCulloch C.E., Iribarren C., et al. Body mass index and risk of end-stage renal failure. Ann.Intern. Med. 2006;144:21-8.
  59. Brozius F.K., Trus R.J. Podocytes, signaling pathways, and vascular factors in diabetic kidney disease. Adv. Chronic. Renal. Dis. 2014;21:304-10.
  60. Borrelli S., Leonardis D., Minutolo R., et al. Epidemiology of CKD Regression in Patients under Nephrology Care. PLoS One. 2015;10(10):e0140138. doi: 10.1371/journal.pone.0140138. eCollection 2015.
  61. Caravaca-Fontdn F., Azevedo L., Luna E., Caravaca F. Patterns of progression of chronic kidney disease at later stages. Clin. Kidney J. 2018;11(2):246-53. doi: 10.1093/ckj/sfx083. [Epub 2017 Jul 28].
  62. Ku E., Johansen K.L., McCulloch C.E. Time-Centered Approach to Understanding Risk Factors for the Progression of CKD. Clin. J. Am. Soc. Nephrol. 2018;13(5):693-701. doi: 10.2215/CJN.10360917. [Epub 2018 Mar 30].
  63. Lee W.C., Lee Y.T., Li L.C., et al. The Number of Comorbidities Predicts Renal Outcomes in Patients with Stage 3-5 Chronic Kidney Disease. J. Clin. Med. 2018;7(12). pii: E493. doi: 10.3390/jcm7120493.
  64. Chase H.S., Hirsch J.S., Mohan S., et al. Presence of early CKD-related metabolic complications predict progression of stage 3 CKD: a case-controlled study. BMC Nephrol. 2014;15:187. doi: 10.1186/1471-2369-15-187.
  65. Totoli C., Carvalho A.B., Ammirati A.L., et al. Associated factors related to chronic kidney disease progression in elderly patients. PLoS One. 2019;14(7):e0219956. doi: 10.1371/journal.pone.0219956.eCollection 2019.
  66. Go A.S., Yang J., Tan T.C., et al. Contemporary rates and predictors of fast progression of chronic kidney disease in adults with and without diabetes mellitus. Kaiser Permanente Northern California CKD Outcomes Study. BMC Nephrol. 2018;19(1):146. doi: 10.1186/s12882-018-0942-1.
  67. Tsai W.C., Wu H.Y., Peng Y.S., et al. Risk Factors for Development and Progression of Chronic Kidney Disease: A Systematic Review and Exploratory Meta-Analysis. Medicine (Baltimore). 2016;95(11):e3013. doi: 10.1097/MD.0000000000003013.
  68. Kumela Goro K., Desalegn Wolide A., Kerga Dibaba F., et al. Patient Awareness, Prevalence, and Risk Factors of Chronic Kidney Disease among Diabetes Mellitus and Hypertensive Patients at Jimma University Medical Center, Ethiopia. Biomed. Res.Int. 2019;2019:2383508. doi: 10.1155/2019/2383508.eCollection 2019.
  69. Земченков А. Ю., Румянцев А. Ш., Смирнов А. В. Оценка эффективности нефропротективной терапии (краткий обзор литературы и данные Санкт-Петербургского регистра). Нефрология. 2018;22(1):58-68. https://doi.org/10.24884/1561-6274-2018-22-1-58-68.
  70. Kefale B., Tadesse Y., Alebachew M., Engidawork E. Management Practice, and Adherence and Its Contributing Factors among Patients with Chronic Kidney Disease at TikurAnbessa Specialized Hospital: A Hospital Based Cross-Sectional Study.Int. J. Nephrol. 2018;2018:2903139. doi: 10.1155/2018/2903139. eCollection 2018.
  71. Rosansky S.J., Schell J., Shega J., et al. Treatment decisions for older adults with advanced chronic kidney disease. BMC Nephrol. 2017;18(1):200. doi: 10.1186/s12882-017-0617-3.
  72. Susanto C., Kooman J., Courtens A.M., Konings C.J.A.M. Conservative care as a treatment option for patients aged 75 years and older with CKD stage V: a National survey in the Netherlands. Eur. Geriatr. Med. 2018;9(2):235-42. doi: 10.1007/s41999-018-0031-9. [Epub 2018 Feb 12].
  73. Aiumtrakul N., Euswas K., Phichedwanichskul K., et al. Disease Clinic Compared with an Outpatient Clinic in a Primary Care Setting: A Retrospective Cohort Study. Cardiovascular and Renal Outcomes in an Excellent Chronic Kidney. Kidney Dis. (Basel). 2019;5(3):144-52. doi: 10.1159/000495464. [Epub 2019 Jan 3].
  74. De Nicola L., Provenzano M., Chiodini P., et al. Independent Role of Underlying Kidney Disease on Renal Prognosis of Patients with Chronic Kidney Disease under Nephrology Care. PLoS One. 2015;10(5):e0127071. doi: 10.1371/journal.pone.0127071.eCollection 2015.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies